Format

Send to

Choose Destination
Fertil Steril. 2001 Nov;76(5):1057-9.

Improvement in insulin sensitivity followed by ovulation and pregnancy in a woman with polycystic ovary syndrome who was treated with rosiglitazone.

Author information

1
Division of Reproductive Endocrinology and Infertility, Department of Gynecology and Obstetrics, Stanford University Medical Center, California 94305-5317, USA. ncataldo@stanford.edu

Abstract

OBJECTIVE:

To determine the metabolic and reproductive effectiveness of rosiglitazone in polycystic ovary syndrome (PCOS).

DESIGN:

Case report.

SETTING:

Academic clinical practice and General Clinical Research Center.

PATIENT(S):

A 25-year-old woman with PCOS.

INTERVENTION(S):

Rosiglitazone maleate, 4 mg daily for 5 months until conception.

MAIN OUTCOME MEASURE(S):

Insulin sensitivity by steady-state plasma glucose technique; serum androgens, progesterone, and hCG; and pelvic ultrasound images.

RESULT(S):

Rosiglitazone treatment for 5 months improved insulin sensitivity, lowered serum free testosterone, and resulted in spontaneous ovulation and conception.

CONCLUSION(S):

Rosiglitazone is a promising insulin sensitizer for treatment of PCOS. Clinical trials are warranted.

PMID:
11704136
DOI:
10.1016/s0015-0282(01)02843-6
[Indexed for MEDLINE]

Supplemental Content

Full text links

Icon for Elsevier Science
Loading ...
Support Center